Virtual sleep-apnea diagnosis and CPAP-adherence compliance layer that keeps CDL drivers certified and on the road.

1. Ognomy's scale to 85,000 virtual visits across all 50 states proves virtual-first OSA diagnosis and treatment can operate as a reimbursable clinical model, de-risking the same clinical playbook for a narrower occupational buyer.
2. The Series A is explicitly earmarked for wearable integration and adherence tooling, confirming investors now see ongoing CPAP compliance tracking, not just diagnosis, as the fundable and differentiated layer that a compliance-record product can build directly on.
3. Ognomy's positioning around long-term adherence support shows the market has already validated that ongoing compliance data, not a single diagnosis visit, is the recurring-revenue product, which is exactly the artifact occupational medical examiners need for DOT recertification.
4. A six-investor syndicate backing a single-condition virtual clinic shows narrow, condition-specific telehealth companies can raise meaningful venture capital, derisking a narrower occupational-compliance spinout of the same underlying clinical thesis.

Catalyst. Ognomy's $20M raise and 85,000-visit scale show virtual-first sleep-apnea diagnosis and adherence tracking is now a proven, investable clinical model, but its funding and product roadmap are aimed at wearable integration and consumer referral channels rather than the regulatory-driven occupational fleet market.

The product is an occupational sleep-apnea compliance program a fleet safety director can trigger the moment a medical examiner flags a driver during a DOT physical. A home sleep test kit ships to the driver's terminal or a designated truck-stop partner location within days, results route to a virtual sleep physician for same-week diagnosis, and if OSA is confirmed the driver starts CPAP with remote titration visits scheduled around dispatch windows instead of clinic hours. A connected CPAP device streams nightly usage data into a compliance dashboard that auto-generates the adherence documentation FMCSA medical examiners require to keep or restore certification, and alerts the fleet safety team before a driver's compliance lapses into a certification risk. Unlike a general virtual sleep clinic, the product's core deliverable is the audit-ready compliance record, not just the clinical visit.

What's different. General virtual sleep clinics like Ognomy compete on consumer convenience and primary-care referral volume. This product competes on a different axis entirely: it is sold to an employer with a regulatory deadline and a single accountable buyer, and its core deliverable is a compliance artifact (the driver qualification file entry), not just a clinical outcome. That makes the sales motion enterprise (per-fleet contracts) rather than consumer (per-patient acquisition), and it creates a data moat: adherence and recertification outcomes tied to specific fleets and FMCSA audit cycles that a general consumer sleep-telehealth company has no reason to build.

Jobs to be done

flowchart LR
  Buyer[Fleet safety and occupational health director] --> Pain[Flagged driver risks losing DOT certification]
  Pain --> Product[Mobile testing plus virtual CPAP compliance pipeline]
  Product --> Outcome[Auditable adherence record keeps driver certified and on the road]

Executive takeaways

• The clinical playbook is already validated: nationwide virtual sleep clinics now run home testing, telemedicine diagnosis, remote CPAP onboarding, and adherence support at meaningful scale.
• The forcing function is operational rather than purely statutory: FMCSA does not impose a bright-line OSA rule, but medical-examiner judgment plus DQ-file recordkeeping makes proof of treatment a recurring fleet problem.
• The clearest whitespace is the employer-facing compliance artifact. Virtual sleep clinics deliver care, and DQ-file vendors manage paperwork, but neither is optimized to turn CPAP adherence data into an audit-ready fleet workflow.
• Go-to-market should start with safety/compliance leaders who already buy DQ automation and feel the cost of expired medical certificates, audit findings, and driver downtime.

Market definition

The relevant market is not generic sleep care. It is the overlap between virtual sleep-apnea diagnosis/treatment and regulated fleet-compliance operations: identifying at-risk CDL drivers, getting them tested quickly, initiating PAP therapy, monitoring adherence, and converting that data into documentation a medical examiner and fleet safety team can use.

Customer and buyer

Day-one users are fleet safety, occupational health, and compliance operators who own DOT medical-card workflows and driver qualification files. The economic buyer is typically a VP of Safety/Compliance, risk leader, or occupational-health leader who feels driver downtime, audit risk, and liability from unmanaged OSA.

Buying triggers

• A DOT physical or recertification visit raises OSA concern and the fleet suddenly needs a sleep-study and compliance path that fits the driver’s work schedule. [39][49][50]
• A driver has PAP treatment but lacks current usage evidence that cleanly supports recertification or file maintenance. [41][49][65]
• An audit, complaint, or compliance review exposes expired medical certificates or weak DQ-file controls, forcing the fleet to replace spreadsheet tracking. [53][54][55]

Willingness to pay

Willingness to pay should be strongest when the product is framed as a compliance-risk and downtime-reduction tool rather than wellness spend. Fleets already buy DQ-file services to prevent paperwork failures, and the downside of untreated or nonadherent OSA includes materially higher preventable crash risk and avoidable audit exposure. [35][53][54][55]

Category dynamics

Growth signal 16.0% CAGR (2026-2036 virtual sleep clinics)

Validation signals

• Ognomy says it has already completed more than 85,000 virtual visits across all 50 states.
• Sleep Review reports BetterNight’s remote CPAP setup program runs at roughly 76% average Medicare compliance and performed similarly to conventional setup in study data.
• GEM reports nationwide availability, employer-benefit partnerships, and a 70% adherence rate.
• Real DOT-audit case studies show expired medical certificates and spreadsheet-based tracking already create fines and immediate software-switching behavior.

Regulatory & technical constraints

• There is no specific FMCSA OSA screening mandate, so the workflow must tolerate examiner discretion and employer-specific escalation policies.
• Certified medical examiners and driver qualification files remain the authoritative certification workflow, so any compliance record must map cleanly to Part 391 paperwork expectations.
• PAP coverage and continued qualification depend on approved sleep-test pathways, documented adherence, and follow-up evidence rather than patient self-report alone.
• Home sleep testing is appropriate only for the right clinical cohort; some drivers will still need escalation to in-lab testing or more specialist oversight.

Competition comes from three adjacent layers. Virtual sleep clinics such as Ognomy, BetterNight, and GEM SLEEP already prove that home testing and remote PAP support work nationally. Fleet-compliance vendors such as Foley and J. J. Keller already own the buyer relationship around DQ-file maintenance. Occupational clinics and regional sleep labs remain the incumbent referral path. The opportunity is to bridge the clinical data layer and the fleet audit workflow before either side fully converges.

Why incumbents do not win by default

• General virtual sleep clinics. They have solved access, HST logistics, and remote adherence support, but their default motion is consumer, provider, payer, or benefits distribution—not employer-owned certification workflow.
• Occupational medicine and examiner workflow. The DOT physical touchpoint is powerful, but today it often ends in referral, manual follow-up, and heterogeneous examiner expectations instead of a closed-loop digital adherence record.
• DQ-file and compliance vendors. These vendors already help fleets manage medical-card and qualification-file deadlines, but they do not own diagnosis, PAP setup, or objective adherence capture.
• PAP and sleep-data platforms. Connected PAP, HST, and sleep-lab software can surface the raw adherence data, but they are not designed to package it into a fleet-specific operating workflow or DQ-file artifact.

This company sells an employer-paid occupational sleep-apnea compliance workflow to self-insured trucking and logistics fleets with 500 to 5,000 CDL drivers. The first product is not a general virtual sleep clinic; it is a closed-loop workflow that moves a driver from an OSA flag at a DOT exam to home testing, virtual diagnosis, CPAP start, and a DQ-file-ready adherence record fast enough to preserve certification. The commercial claim is that fleets will pay from safety and compliance budgets because the cost of manual referrals is lost driving days, audit exposure, and preventable crash risk, not just poor patient experience. The underlying clinical stack is already de-risked by Ognomy, BetterNight, and GEM, which show that nationwide virtual sleep testing, PAP onboarding, and remote adherence support are operationally viable. What is still unproven is buyer behavior: research shows direct fleet-buyer evidence remains thin, and the business only works if mid-size self-insured fleets centralize OSA escalation enough to buy one enterprise workflow. The beachhead should therefore be concentrated fleets that already coordinate DOT exams in-house, use DQ-file tooling, and can start with a single terminal cluster or recertification cohort. Research sizes that beachhead at about a $50.7M SAM and a plausible $4.5M year-3 SOM, so the venture case depends on later expansion into other safety-sensitive worker categories rather than trucking alone. Differentiation comes from packaging objective PAP data into a conservative compliance artifact and embedding it in existing fleet workflows before virtual sleep clinics or compliance vendors converge on the same use case. This should be financed as a pre-seed plan and judged by whether the first paid pilots cut flag-to-diagnosis time, win examiner acceptance of the generated packet, and onboard fleets without bespoke integrations.

Problem

• Flagged CDL drivers can lose or shorten DOT medical certification because fleets still rely on referrals to occupational clinics or regional sleep labs that do not match dispatch schedules and often take weeks to complete.
• Even when a driver is already on PAP therapy, fleets still assemble adherence proof manually across clinics, device portals, and paper letters, which creates DQ-file gaps, audit exposure, and avoidable driver downtime.
• Existing substitutes each own only one layer of the workflow: virtual sleep clinics deliver care, DQ vendors manage documents, and occupational clinics perform exams, but no system closes the loop from OSA flag to accepted compliance record.

Solution

• Trigger a closed-loop workflow the moment a DOT exam raises OSA concern, including terminal-routed home sleep test logistics, physician-directed virtual diagnosis, and dispatch-aware PAP onboarding.
• Convert connected PAP usage into conservative compliance packets and lapse alerts that the fleet can attach to the driver qualification file instead of manually chasing letters and screenshots.
• Keep the workflow clinically safe by escalating non-appropriate cases to in-lab testing or specialist review and keeping employer-facing reporting limited to certification-relevant artifacts.

Why we win

• The first buyer is an enterprise operator with a live compliance trigger and measurable downtime cost, which is a faster sales wedge than competing for consumer sleep-care demand.
• The core clinical playbook is already validated by scaled virtual sleep clinics, so the startup can focus its product effort on the missing compliance workflow rather than inventing tele-sleep medicine from scratch.
• Every deployment compounds reusable DQ-file templates, examiner-ready report formats, and carrier-specific intervention data linking adherence behavior to certification outcomes.
• The company can partner for HST ordering, sleep-physician coverage, and PAP setup while owning the employer workflow layer that incumbents do not yet optimize for fleets.

Milestones

flowchart LR
  Wedge[Flagged-driver compliance wedge] --> MVP[Terminal-first MVP]
  MVP --> Proof[Faster diagnosis plus accepted DQ packet]
  Proof --> Expansion[Multi-fleet contracts and adjacent sectors]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 3 of the first 10 target fleets centralize OSA follow-up enough to run a single enterprise pilot.
• Pilot fleets can reduce median time from OSA flag to diagnosis to 7 days or less.
• At least 75% of early compliance packets are accepted without material rework by medical examiners.
• One HST vendor, one PAP data workflow, and two DQ-file systems cover most of the first 10 fleet opportunities.
• At least half of paid pilots convert to annual contracts at economics consistent with a 70% gross-margin target.

Open diligence questions

• Who owns budget and workflow when a driver is flagged: safety, occupational health, benefits, or an outside clinic?
• How standardized are acceptable PAP-compliance packets across examiner networks and regions?
• Which HST, PAP, and DQ-file systems dominate the target fleet cohort?
• How many flagged drivers per year does a typical 1,200-driver fleet actually route through centralized follow-up?
• Will DQ vendors distribute this product, or will they treat it as a feature to build internally?

Model sanity

• Revenue engine. Base-case revenue is driven by growing from 3 paid fleets at Y1 exit to 40 fleets at Y3 exit while normalized annual ARPU standardizes at about $114K per fleet.
• Must go right. The narrow HST, PAP, and DQ workflow must stay reusable enough that one channel partner can help move the company from 10 fleets in Y2 to 40 fleets in Y3 without a services-heavy headcount spike.
• Model breaks if. If sales cycles drift toward 9 months and packet acceptance remains bespoke, downside cash falls below zero before the company reaches the planned 40-fleet scale.
• Next-round proof. The next financing is justified by reaching 8-10 live fleets, converting pilots into annual contracts, and proving accepted packets plus diagnosis speed that support partner-led expansion.

Scenarios

Sensitivity

flowchart LR
  Outreach[Founder plus partner outreach] --> Pilots[Paid pilots]
  Pilots --> Fleets[Paying fleets]
  Fleets --> Drivers[Monitored flagged drivers]
  Drivers --> Revenue[Subscription plus packet revenue]
  Revenue --> GrossProfit[Gross profit after partner clinical and QA costs]
  GrossProfit --> Cash[Cash runway]

Flags: Base case requires the company to hit the full researched 40-fleet year-3 SOM, so GTM slippage leaves limited room before the next raise is pressured. · Gross-margin improvement assumes manual packet QA and connector work become materially more repeatable after the first 10 fleets. · CAC and churn remain heuristic because no observed fleet cohorts exist yet, so the first paid pilots can move unit economics materially. · Forty fleets on 9 year-end FTE only works if partner-delivered clinical operations and standardized integrations absorb most implementation variance.

• Incumbent expansion risk. Ognomy or another well-funded virtual sleep clinic could add an occupational/fleet compliance module once they notice the segment, leveraging their existing clinical network and capital advantage. Mitigation: Move first on driver qualification file integrations and fleet safety software partnerships that create switching costs a later entrant cannot replicate quickly.
• Regulatory and reimbursement dependency. The business model depends on FMCSA medical certification rules continuing to treat OSA adherence as a certification factor; a policy change could remove the forcing function entirely. Mitigation: Build the adherence-tracking and compliance-reporting engine so it is valuable for general occupational health and workers' comp risk management even if the specific FMCSA rule changes.
• Field logistics failure. Mobile test kit distribution and titration scheduling around unpredictable dispatch routes could break down operationally, undermining the core speed advantage over incumbent referral clinics. Mitigation: Start with a small number of high-volume terminal hubs to prove the logistics model before expanding to distributed, less predictable truck-stop drop points.